XBiotech Inc. (NASDAQ:XBIT – Get Free Report) Director John Simard purchased 368,524 shares of the firm’s stock in a transaction that occurred on Monday, October 26th. The shares were acquired at an average price of $1.93 per share, with a total value of $711,251.32. Following the purchase, the director owned 4,191,690 shares in the company, valued at $8,089,961.70. This trade represents a 9.64% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
XBiotech Price Performance
Shares of XBiotech stock opened at $1.88 on Friday. XBiotech Inc. has a 1 year low of $1.80 and a 1 year high of $3.44. The company’s fifty day moving average is $2.15 and its two-hundred day moving average is $2.32.
XBiotech (NASDAQ:XBIT – Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.03 by ($0.25).
Institutional Investors Weigh In On XBiotech
A number of hedge funds have recently added to or reduced their stakes in XBIT. BlackRock Inc. acquired a new position in XBiotech during the 2nd quarter worth approximately $739,000. Empowered Funds LLC acquired a new stake in shares of XBiotech in the 2nd quarter valued at approximately $137,000. Bank of New York Mellon Corp acquired a new stake in shares of XBiotech in the 2nd quarter valued at approximately $91,000. GSA Capital Partners LLP acquired a new stake in shares of XBiotech in the 2nd quarter valued at approximately $71,000. Finally, Connor Clark & Lunn Investment Management Ltd. purchased a new stake in shares of XBiotech in the second quarter valued at approximately $64,000. Institutional investors and hedge funds own 55.70% of the company’s stock.
Wall Street Analyst Weigh In
Separately, Weiss Ratings upgraded shares of XBiotech from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Friday, October 16th. One analyst has rated the stock with a Sell rating. According to data from MarketBeat.com, the company has an average rating of “Sell”.
View Our Latest Stock Analysis on XBiotech
About XBiotech
XBiotech, Inc is a biotechnology company focused on discovering, developing and commercializing therapies based on True Human antibodies. Its research platform is designed to produce fully human antibodies that target specific biological pathways involved in inflammation and other serious diseases.
The company’s leading investigational product is bermekimab, an antibody designed to neutralize interleukin-1 alpha, a protein associated with inflammation and disease progression. Bermekimab has been evaluated in clinical studies involving conditions including cancer, inflammatory skin diseases and other disorders.
Read More
- Five stocks we like better than XBiotech
- Amazon’s Record Margins Couldn’t Stop the Sell-Off—Here’s Why
- DoorDash’s $17 Billion Bet on Instacart Faces a Long Regulatory Road Ahead
- FTC Puts A Wrinkle In the Cintas and UniFirst Merger
- Breaching the Valuation: The Real Reason Fortinet Dropped
Receive News & Ratings for XBiotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for XBiotech and related companies with MarketBeat.com's FREE daily email newsletter.
